Skip to content

    SRF Limited

    SRF
    Chemicals·20 Jan 2026
    Management Summary

    SRF reported a healthy Q3 FY26 with 6% revenue growth and 60% PAT expansion, primarily driven by strong performance in the Fluorochemicals segment. However, Specialty Chemicals and Performance Films faced headwinds from Chinese competition, pricing pressure, and demand deferrals. The company is strategically investing in new generation gases and expanding its pharma intermediate capacity to diversify its portfolio and mitigate risks.

    Highlights

    5
    • Gross operating revenue grew 6% to INR3,713 crore.

    • EBIT increased 23% year-on-year from INR529 crore to INR653 crore.

    • PAT expanded 60% year-on-year to INR433 crore.

    • Chemicals Business revenue grew 22% to INR1,825 crore, driven by higher refrigerant volumes and operational efficiencies.

    • Fluorochemicals business delivered a record quarter, supported by firm global HFC prices.

    Concerns

    6
    • Specialty Chemicals facing persistent pricing pressure from Chinese competitors, impacting financial performance.

    • Continued deferment in offtake for certain key products by agro majors.

    • Performance Films & Foils revenue declined 3% year-on-year.

    • Negative impact from forward positions on rupee-dollar hedges due to unprecedented rupee depreciation.

    • Technical Textiles (Belting Fabrics) under pressure due to aggressive Chinese pricing and reduced demand.

    • Coated Fabrics domestic demand soft, impacted by cheaper Chinese imports.

    Key financials

    Single quarter

    03 metrics
    1. 01Gross Operating Revenue₹3,713 Cr+6%YoY
    2. 02EBIT₹653 Cr+23%YoY
    3. 03PAT₹433 Cr+60%YoY

    Segment breakdown

    • Chemicals Business₹1,825 Cr50.4%
    • Performance Films & Foils₹1,342 Cr37.1%
    • Technical Textiles₹454 Cr12.5%
    Donut· Share of Revenue

    Capital allocation

    3
    medium confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Debt disclosed

    Dividend

    ₹5/share (interim)

    Guidance & targets

    6
    CategoryTargetPriority
    Capex
    Second pharma intermediate plant investment
    INR180 crore
    High
    Capex
    First stage investments for Odisha site (new generation gases)
    INR1,500-2,000 crore
    High
    Segment Contribution
    Pharma business share of total specialty chemicals
    at least 20%
    Medium
    New Product Launches
    New Active Ingredient (AI) launches
    one in FY26, couple in FY27
    High
    Capacity
    New fluoropolymer plants (Chemours contract)
    coming up
    High
    Growth
    Specialty Chemicals growth
    fall short of 20%
    High

    What to watch in Q4 FY26

    5

    Specialty Chemicals margin improvement

    Q4 FY26
    CurrentFacing persistent pricing pressure, margins impacted
    TargetImproved margins and better performance

    Why it matters

    Specialty Chemicals is a key segment facing headwinds; improvement signals recovery and validates management's strategy.

    It's coming definitely from Specialty Chemicals. Like I said, the Specialty Chemicals business has had a more challenging time, so it has come from that. But I'm sure that we'll see💬 a better performance in quarter 4.

    Risks & concerns

    5
    RiskSeverity

    Persistent pricing pressure from Chinese competitors in Specialty Chemicals

    Irrational pricing from Chinese competitors impacting margins; SRF protecting market share and volumes.Management acknowledged

    high

    Continued deferment offtake for certain key agro products

    Agro majors delaying purchases, though signs of revival are emerging.Management acknowledged

    medium

    Negative impact from rupee-dollar hedge positions due to rupee depreciation

    Unprecedented rupee depreciation negatively impacted forward positions, expected for a few more quarters.Management acknowledged

    medium

    Volatility in US market for R32 due to tariff uncertainty

    Tariff situation makes business transactional rather than relationship-oriented, impacting buying behavior.Management acknowledged

    medium

    Competitive pressure and cheaper imports in Performance Films & Foils

    Sustained competitive pressure from cheaper imports in international operations and soft domestic demand.Management acknowledged

    medium

    Q&A highlights

    8

    “the first stage of investments in the Odisha site will probably be in the range of INR1,500 crore to INR2,000 crore. So in that sense, the capex for financial year '27 also remains on a strong wicket.”

    Management confirms significant capex for new generation gases, aligning with previous guidance and highlighting long-term strategic focus despite global volatility.

    asked by Arjun Khanna

    2 min read6 chapters

    Detailed Narrative

    01

    Robust Q3 FY26 Performance Despite Headwinds

    SRF delivered a healthy performance in Q3 FY26, with gross operating revenue growing 6% to INR3,713 crore. EBIT saw a significant 23% year-on-year increase, reaching INR653 crore, up from INR529 crore in Q3 FY25. Net Profit After Tax (PAT) expanded by an impressive 60% year-on-year to INR433 crore, reflecting improved operational efficiency and disciplined cost management amidst global uncertainties.

    02

    Chemicals Business Driven by Fluorochemicals, Specialty Faces Pressure

    The Chemicals Business reported a strong revenue growth of 22%, increasing from INR1,496 crore in Q3 FY25 to INR1,825 crore in Q3 FY26. This growth was primarily fueled by higher refrigerant volumes and enhanced operational efficiencies in Fluorochemicals, which had a record quarter. However, the Specialty Chemicals segment continued to face persistent pricing pressure from Chinese competitors, leading SRF to prioritize market share and volumes over aggressive pricing.

    03

    Strategic Expansion into Pharma Segment

    To mitigate risks associated with the cyclical nature of the agro-chemical business, SRF is accelerating its expansion into the pharma segment. The company is investing INR180 crore in a second pharma intermediate plant at its Dahej site, which is expected to be commissioned within the next 8 months. This move aims to increase the pharma business's contribution to at least 20% of the total specialty chemicals portfolio, leveraging a robust pipeline of new molecules and growing customer base.

    04

    New Generation Gases and Odisha Site Development

    SRF is making significant progress on its next-generation refrigerant gases project, which will be housed at a new site in Odisha. The company has applied for necessary regulatory clearances and anticipates initial investments of INR1,500 crore to INR2,000 crore for this site in FY27. This strategic investment aligns with the inevitable global transition to new generation gases under the Kigali Amendment, positioning SRF for long-term growth in this evolving market.

    05

    Performance Films & Foils Navigates Competitive Landscape

    The Performance Films & Foils business experienced a 3% year-on-year revenue decline to INR1,342 crore, although EBIT improved slightly to INR95 crore from INR90 crore in Q3 FY25. This segment faced challenges from lower BOPET and BOPP volumes in the domestic market and sustained competitive pressure from cheaper imports in international markets. Encouragingly, recent Chinese mandates to cut BOPET capacity by 20% have led to some price improvement, with further cuts expected post-Lunar holidays.

    06

    Capital Allocation and Shareholder Returns

    The Board approved a second interim dividend of INR5 per share, resulting in a cash outflow of INR148.21 crore, following a previous INR4 per share dividend. SRF maintains a strong capex outlook, with significant investments planned for the new pharma plant and the Odisha site for new generation gases. While global interest rate reductions are beneficial, the company noted a negative impact from rupee-dollar hedges due to unprecedented🌐 rupee depreciation, though a weak rupee is generally favorable for its export-oriented business.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.